Financhill
Buy
63

AMED Quote, Financials, Valuation and Earnings

Last price:
$93.39
Seasonality move :
10.31%
Day range:
$93.25 - $94.22
52-week range:
$82.15 - $98.95
Dividend yield:
0%
P/E ratio:
34.48x
P/S ratio:
1.31x
P/B ratio:
2.56x
Volume:
129K
Avg. volume:
392.4K
1-year change:
-2.88%
Market cap:
$3.1B
Revenue:
$2.3B
EPS (TTM):
$2.71

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
AMED
Amedisys
$615.7M $1.08 4.11% 40.38% $96.86
ADUS
Addus HomeCare
$350.5M $1.52 20.51% 33.48% $136.10
CHE
Chemed
$658M $6.21 9.18% 29.89% $677.33
HCAT
Health Catalyst
$85.2M $0.08 6.46% -99.77% $8.09
OPCH
Option Care Health
$1.4B $0.43 10.25% 32.25% $38.56
OPRX
OptimizeRx
$24.7M $0.09 18.36% -91.67% $15.08
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
AMED
Amedisys
$93.43 $96.86 $3.1B 34.48x $0.00 0% 1.31x
ADUS
Addus HomeCare
$112.16 $136.10 $2.1B 25.32x $0.00 0% 1.65x
CHE
Chemed
$569.57 $677.33 $8.3B 27.74x $0.50 0.33% 3.44x
HCAT
Health Catalyst
$3.65 $8.09 $254M -- $0.00 0% 0.73x
OPCH
Option Care Health
$31.41 $38.56 $5.1B 25.33x $0.00 0% 1.03x
OPRX
OptimizeRx
$11.65 $15.08 $215.5M -- $0.00 0% 2.27x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
AMED
Amedisys
23.6% -0.140 12.01% 1.23x
ADUS
Addus HomeCare
16.64% 0.970 10.92% 1.61x
CHE
Chemed
-- 0.460 -- 1.58x
HCAT
Health Catalyst
50.4% 1.824 121.45% 1.20x
OPCH
Option Care Health
45.12% 0.749 19.41% 0.91x
OPRX
OptimizeRx
21.84% -2.555 20.29% 2.69x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
AMED
Amedisys
$260.7M $60.1M 5.72% 7.55% 16.41% -$5.1M
ADUS
Addus HomeCare
$107.7M $30.5M 7.78% 8.66% 9.18% $17.1M
CHE
Chemed
$216.4M $94.8M 26.04% 26.04% 14.84% $19.5M
HCAT
Health Catalyst
$36.2M -$20.2M -10.75% -20.06% -20.41% -$5.1M
OPCH
Option Care Health
$263.1M $79.2M 8.53% 15.22% 5.76% -$16.6M
OPRX
OptimizeRx
$13.3M -$2.1M -10.09% -13.03% -9.06% $3.8M

Amedisys vs. Competitors

  • Which has Higher Returns AMED or ADUS?

    Addus HomeCare has a net margin of 10.26% compared to Amedisys's net margin of 6.29%. Amedisys's return on equity of 7.55% beat Addus HomeCare's return on equity of 8.66%.

    Company Gross Margin Earnings Per Share Invested Capital
    AMED
    Amedisys
    43.84% $1.84 $1.6B
    ADUS
    Addus HomeCare
    31.89% $1.16 $1.2B
  • What do Analysts Say About AMED or ADUS?

    Amedisys has a consensus price target of $96.86, signalling upside risk potential of 3.67%. On the other hand Addus HomeCare has an analysts' consensus of $136.10 which suggests that it could grow by 21.35%. Given that Addus HomeCare has higher upside potential than Amedisys, analysts believe Addus HomeCare is more attractive than Amedisys.

    Company Buy Ratings Hold Ratings Sell Ratings
    AMED
    Amedisys
    0 9 1
    ADUS
    Addus HomeCare
    7 0 0
  • Is AMED or ADUS More Risky?

    Amedisys has a beta of 0.964, which suggesting that the stock is 3.612% less volatile than S&P 500. In comparison Addus HomeCare has a beta of 0.850, suggesting its less volatile than the S&P 500 by 14.958%.

  • Which is a Better Dividend Stock AMED or ADUS?

    Amedisys has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addus HomeCare offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amedisys pays -- of its earnings as a dividend. Addus HomeCare pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AMED or ADUS?

    Amedisys quarterly revenues are $594.8M, which are larger than Addus HomeCare quarterly revenues of $337.7M. Amedisys's net income of $61M is higher than Addus HomeCare's net income of $21.2M. Notably, Amedisys's price-to-earnings ratio is 34.48x while Addus HomeCare's PE ratio is 25.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amedisys is 1.31x versus 1.65x for Addus HomeCare. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AMED
    Amedisys
    1.31x 34.48x $594.8M $61M
    ADUS
    Addus HomeCare
    1.65x 25.32x $337.7M $21.2M
  • Which has Higher Returns AMED or CHE?

    Chemed has a net margin of 10.26% compared to Amedisys's net margin of 11.09%. Amedisys's return on equity of 7.55% beat Chemed's return on equity of 26.04%.

    Company Gross Margin Earnings Per Share Invested Capital
    AMED
    Amedisys
    43.84% $1.84 $1.6B
    CHE
    Chemed
    33.45% $4.86 $1.2B
  • What do Analysts Say About AMED or CHE?

    Amedisys has a consensus price target of $96.86, signalling upside risk potential of 3.67%. On the other hand Chemed has an analysts' consensus of $677.33 which suggests that it could grow by 18.92%. Given that Chemed has higher upside potential than Amedisys, analysts believe Chemed is more attractive than Amedisys.

    Company Buy Ratings Hold Ratings Sell Ratings
    AMED
    Amedisys
    0 9 1
    CHE
    Chemed
    2 0 0
  • Is AMED or CHE More Risky?

    Amedisys has a beta of 0.964, which suggesting that the stock is 3.612% less volatile than S&P 500. In comparison Chemed has a beta of 0.593, suggesting its less volatile than the S&P 500 by 40.659%.

  • Which is a Better Dividend Stock AMED or CHE?

    Amedisys has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Chemed offers a yield of 0.33% to investors and pays a quarterly dividend of $0.50 per share. Amedisys pays -- of its earnings as a dividend. Chemed pays out 8.97% of its earnings as a dividend. Chemed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios AMED or CHE?

    Amedisys quarterly revenues are $594.8M, which are smaller than Chemed quarterly revenues of $646.9M. Amedisys's net income of $61M is lower than Chemed's net income of $71.8M. Notably, Amedisys's price-to-earnings ratio is 34.48x while Chemed's PE ratio is 27.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amedisys is 1.31x versus 3.44x for Chemed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AMED
    Amedisys
    1.31x 34.48x $594.8M $61M
    CHE
    Chemed
    3.44x 27.74x $646.9M $71.8M
  • Which has Higher Returns AMED or HCAT?

    Health Catalyst has a net margin of 10.26% compared to Amedisys's net margin of -29.9%. Amedisys's return on equity of 7.55% beat Health Catalyst's return on equity of -20.06%.

    Company Gross Margin Earnings Per Share Invested Capital
    AMED
    Amedisys
    43.84% $1.84 $1.6B
    HCAT
    Health Catalyst
    45.63% -$0.35 $759.7M
  • What do Analysts Say About AMED or HCAT?

    Amedisys has a consensus price target of $96.86, signalling upside risk potential of 3.67%. On the other hand Health Catalyst has an analysts' consensus of $8.09 which suggests that it could grow by 121.67%. Given that Health Catalyst has higher upside potential than Amedisys, analysts believe Health Catalyst is more attractive than Amedisys.

    Company Buy Ratings Hold Ratings Sell Ratings
    AMED
    Amedisys
    0 9 1
    HCAT
    Health Catalyst
    7 4 0
  • Is AMED or HCAT More Risky?

    Amedisys has a beta of 0.964, which suggesting that the stock is 3.612% less volatile than S&P 500. In comparison Health Catalyst has a beta of 1.559, suggesting its more volatile than the S&P 500 by 55.873%.

  • Which is a Better Dividend Stock AMED or HCAT?

    Amedisys has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Health Catalyst offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amedisys pays -- of its earnings as a dividend. Health Catalyst pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AMED or HCAT?

    Amedisys quarterly revenues are $594.8M, which are larger than Health Catalyst quarterly revenues of $79.4M. Amedisys's net income of $61M is higher than Health Catalyst's net income of -$23.7M. Notably, Amedisys's price-to-earnings ratio is 34.48x while Health Catalyst's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amedisys is 1.31x versus 0.73x for Health Catalyst. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AMED
    Amedisys
    1.31x 34.48x $594.8M $61M
    HCAT
    Health Catalyst
    0.73x -- $79.4M -$23.7M
  • Which has Higher Returns AMED or OPCH?

    Option Care Health has a net margin of 10.26% compared to Amedisys's net margin of 3.51%. Amedisys's return on equity of 7.55% beat Option Care Health's return on equity of 15.22%.

    Company Gross Margin Earnings Per Share Invested Capital
    AMED
    Amedisys
    43.84% $1.84 $1.6B
    OPCH
    Option Care Health
    19.73% $0.28 $2.5B
  • What do Analysts Say About AMED or OPCH?

    Amedisys has a consensus price target of $96.86, signalling upside risk potential of 3.67%. On the other hand Option Care Health has an analysts' consensus of $38.56 which suggests that it could grow by 22.75%. Given that Option Care Health has higher upside potential than Amedisys, analysts believe Option Care Health is more attractive than Amedisys.

    Company Buy Ratings Hold Ratings Sell Ratings
    AMED
    Amedisys
    0 9 1
    OPCH
    Option Care Health
    6 1 0
  • Is AMED or OPCH More Risky?

    Amedisys has a beta of 0.964, which suggesting that the stock is 3.612% less volatile than S&P 500. In comparison Option Care Health has a beta of 0.763, suggesting its less volatile than the S&P 500 by 23.686%.

  • Which is a Better Dividend Stock AMED or OPCH?

    Amedisys has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Option Care Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amedisys pays -- of its earnings as a dividend. Option Care Health pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AMED or OPCH?

    Amedisys quarterly revenues are $594.8M, which are smaller than Option Care Health quarterly revenues of $1.3B. Amedisys's net income of $61M is higher than Option Care Health's net income of $46.7M. Notably, Amedisys's price-to-earnings ratio is 34.48x while Option Care Health's PE ratio is 25.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amedisys is 1.31x versus 1.03x for Option Care Health. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AMED
    Amedisys
    1.31x 34.48x $594.8M $61M
    OPCH
    Option Care Health
    1.03x 25.33x $1.3B $46.7M
  • Which has Higher Returns AMED or OPRX?

    OptimizeRx has a net margin of 10.26% compared to Amedisys's net margin of -10.03%. Amedisys's return on equity of 7.55% beat OptimizeRx's return on equity of -13.03%.

    Company Gross Margin Earnings Per Share Invested Capital
    AMED
    Amedisys
    43.84% $1.84 $1.6B
    OPRX
    OptimizeRx
    60.85% -$0.12 $148.8M
  • What do Analysts Say About AMED or OPRX?

    Amedisys has a consensus price target of $96.86, signalling upside risk potential of 3.67%. On the other hand OptimizeRx has an analysts' consensus of $15.08 which suggests that it could grow by 29.47%. Given that OptimizeRx has higher upside potential than Amedisys, analysts believe OptimizeRx is more attractive than Amedisys.

    Company Buy Ratings Hold Ratings Sell Ratings
    AMED
    Amedisys
    0 9 1
    OPRX
    OptimizeRx
    4 1 0
  • Is AMED or OPRX More Risky?

    Amedisys has a beta of 0.964, which suggesting that the stock is 3.612% less volatile than S&P 500. In comparison OptimizeRx has a beta of 1.283, suggesting its more volatile than the S&P 500 by 28.349%.

  • Which is a Better Dividend Stock AMED or OPRX?

    Amedisys has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OptimizeRx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amedisys pays -- of its earnings as a dividend. OptimizeRx pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AMED or OPRX?

    Amedisys quarterly revenues are $594.8M, which are larger than OptimizeRx quarterly revenues of $21.9M. Amedisys's net income of $61M is higher than OptimizeRx's net income of -$2.2M. Notably, Amedisys's price-to-earnings ratio is 34.48x while OptimizeRx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amedisys is 1.31x versus 2.27x for OptimizeRx. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AMED
    Amedisys
    1.31x 34.48x $594.8M $61M
    OPRX
    OptimizeRx
    2.27x -- $21.9M -$2.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Gartner Stock Be in 5 Years?
Where Will Gartner Stock Be in 5 Years?

If you’ve ever wondered what it’s like to invest in…

Rambus (RMBS) Stock Forecast, Can the Rally Continue in 2025?
Rambus (RMBS) Stock Forecast, Can the Rally Continue in 2025?

Rambus has flown under the radar, but the numbers tell…

Celsius Stock Forecast: Will Earnings Spark Another Surge?
Celsius Stock Forecast: Will Earnings Spark Another Surge?

Energy drink seller Celsius Holdings, Inc. (NASDAQ:CELH) has reported somewhat…

Stock Ideas

Buy
65
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 38x

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 45x

Sell
33
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Alerts

Buy
60
MRUS alert for May 24

Merus NV [MRUS] is up 32.55% over the past day.

Buy
57
RGC alert for May 24

Regencell Bioscience Holdings [RGC] is up 28.43% over the past day.

Buy
90
OKLO alert for May 24

Oklo [OKLO] is up 23.11% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock